- Home
- LQDA
LQDA
Liquidia Corporation
as 09-17-2025 4:00pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 2.5B | IPO Year: | 2018 |
| Target Price: | $32.11 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.68 - $29.94 | Next Earning Date: | 11-12-2025 |
| Revenue: | $19,322,000 | Revenue Growth: | 30.20% |
| Revenue Growth (this year): | 405.58% | Revenue Growth (next year): | 373.93% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| SINGH RAMAN | LQDA | Director | Sep 15 '25 | Sell | $25.81 | 45,524 | $1,174,974.44 | 31,255 | |
| SINGH RAMAN | LQDA | Director | Sep 3 '25 | Sell | $29.42 | 7,500 | $220,650.00 | 31,255 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Sep 2 '25 | Sell | $28.76 | 70,692 | $2,023,670.60 | 155,254 | |
| Kaseta Michael | LQDA | CFO and COO | Sep 2 '25 | Sell | $29.05 | 1,148 | $33,349.40 | 358,448 | |
| Adair Jason | LQDA | Chief Business Officer | Sep 2 '25 | Sell | $29.05 | 451 | $13,101.55 | 172,980 | |
| Schundler Russell | LQDA | General Counsel | Sep 2 '25 | Sell | $29.05 | 1,063 | $30,880.15 | 580,098 | |
| Manning Paul B | LQDA | Director | Sep 2 '25 | Sell | $28.91 | 328,268 | $9,446,331.66 | 430,828 | |
| Manning Paul B | LQDA | Director | Aug 29 '25 | Sell | $27.62 | 188,232 | $5,198,967.84 | 430,828 | |
| Krepp Sarah | LQDA | Chief Human Resource Officer | Aug 29 '25 | Sell | $29.05 | 209 | $6,071.45 | 143,130 | |
| Boyle Dana | LQDA | Chief Accounting Officer | Aug 29 '25 | Sell | $29.05 | 296 | $8,598.80 | 186,649 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
Insider Monkey
14 days ago
Jefferies Highlights Yutrepia’s Market Edge in Supporting a Buy on Liquidia (LQDA)
Insider Monkey
a month ago
Court Victory and Fresh Funding Propel Growth at Liquidia Corporation
MT Newswires
3 months ago
BTIG Cuts Price Target on Liquidia to $40 From $45, Maintains Buy Rating
MT Newswires
3 months ago
Liquidia Gets $50 Million From Healthcare Royalty
GlobeNewswire
3 months ago
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
Simply Wall St.
3 months ago
Top Growth Companies With Insider Stakes In June 2025
Investor's Business Daily
3 months ago
Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia
MT Newswires
4 months ago
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.